Companies / Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc.
JNCECIK 1640455
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| May 3, 2023 | Concentra Biosciences, LLC 10% owner | Other Other (per filing) | Common Stock | $97.38M | +10K | 10,000 | low |
| May 3, 2023 | Tang Kevin C Director | Other Other (per filing) | Common Stock | $97.38M | +10K | 10,000 | low |
| Mar 1, 2021 | Third Rock Ventures II, L.P. 10% owner | Sell Open-market sale | Common Stock | $17.04M | -1.4M -15.76% | 7,750,349 | high |
| Nov 12, 2021 | Third Rock Ventures III, L.P. 10% owner | Sell Open-market sale | Common Stock | $15.92M | -1.9M -62.32% | 1,148,780 | high |
| May 3, 2023 | Tang Kevin C Director | Other Shares tendered | Common Stock | $9.81M | -5.3M -100.00% | 0 | low |
| May 25, 2021 | Third Rock Ventures II, L.P. 10% owner | Sell Open-market sale | Common Stock | $4.42M | -553K -8.50% | 5,947,829 | medium |
| Jan 21, 2021 | Murray Richard /Ca/ CEO | Sell Open-market sale | Common Stock | $404.2K | -34K -19.28% | 140,371 | medium |
| Jan 19, 2021 | Murray Richard /Ca/ CEO | Sell Open-market sale | Common Stock | $383.6K | -40K -22.18% | 140,371 | medium |